Subcutaneous cardioverter-defibrillator implantation after cardiac surgery and endocardial device infection

Main Article Content

Daniel Ruiz Domínguez
Raúl Cano del Val Meraz

Abstract

Introduction: The implant of a Subcutaneous Implantable Automatic Defibrillator (ICD) is not common in some countries due to their specific indications, the novelty of the technique and the device, the large infrastructure needed, and the high cost. In this paper, we present the 17th implantation of this device in our country.
Background: This is a man with heart failure with reduced ejection fraction (HFrEF) of ischemic etiology associated with mitral and tricuspid valve disease in whom coronary revascularization surgery, mitral valve replacement, and tricuspid annuloplasty were initially performed.
Results: During follow-up and after optimal medical treatment, a Subcutaneous ICD was implanted as primary prevention for sudden cardiac death; during follow-up, he developed an infection of the implant site, and after ruling out endocarditis, subcutaneous ICD placement was necessary.
Conclusion: This case exposes the clinical scenarios for the indication of a subcutaneous ICD, its effectiveness in reversing sudden death, and recovery after implantation.
Relevant points: Although the indications for Implantable Cardioverter-Defibrillator (ICD) placement are well established in both national and international literature, subcutaneous implantation of this device remains uncommon in our country. This case is relevant given the limited local experience and seeks to provide Mexican cardiologists with a clearer understanding of the indications and nature of the procedure.

Downloads

Download data is not yet available.

Article Details

Ruiz Domínguez, D., & Cano del Val Meraz, R. (2025). Subcutaneous cardioverter-defibrillator implantation after cardiac surgery and endocardial device infection. Journal of Cardiovascular Medicine and Cardiology, 12(8), 089–092. https://doi.org/10.17352/2455-2976.000232
Case Reports

Copyright (c) 2025 Domínguez DR, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation. 1998;98(21):2334-51. Available from: https://doi.org/10.1161/01.cir.98.21.2334 DOI: https://doi.org/10.1161/01.CIR.98.21.2334

Hauser RG. The subcutaneous implantable cardioverter-defibrillator. J Am Coll Cardiol. 2013;61(1):20-2. Available from: https://doi.org/10.1016/j.jacc.2012.07.069 DOI: https://doi.org/10.1016/j.jacc.2012.07.069

Khi Yung Fong, Colin Jun Rong Ng, Yue Wang, Yeo C, Tan VH. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta-Analysis of Randomized Trials and Propensity Score–Matched Studies. J Am Heart Assoc. 2022;11(11):e024756. Available from: https://doi.org/10.1161/jaha.121.024756 DOI: https://doi.org/10.1161/JAHA.121.024756

van Rees JB, de Bie MK, Thijssen J, Borleffs CJW, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices. J Am Coll Cardiol. 2011;58(10):995-1000. Available from: https://doi.org/10.1016/j.jacc.2011.06.007 DOI: https://doi.org/10.1016/j.jacc.2011.06.007

Maisel WH, Kramer DB. Implantable cardioverter-defibrillator lead performance. Circulation. 2008;117(21):2721-3. Available from: https://doi.org/10.1161/circulationaha.108.776807 DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.776807

Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, et al. An entirely subcutaneous implantable cardioverter–defibrillator. N Engl J Med. 2010;363(1):36-44. Available from: https://doi.org/10.1056/nejmoa0909545 DOI: https://doi.org/10.1056/NEJMoa0909545

Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, et al. Safety and efficacy of a totally subcutaneous implantable cardioverter defibrillator. Circulation. 2013;128(9):944-53. Available from: https://doi.org/10.1161/circulationaha.113.003042 DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.003042

Lambiase PD, Barr C, Theuns DAMJ, Knops R, Neuzil P, Johansen JB, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35(25):1657-65. Available from: https://doi.org/10.1093/eurheartj/ehu112 DOI: https://doi.org/10.1093/eurheartj/ehu112

Pagore PA, Gaidhane SA. Effects and Complications of Subcutaneous Implantable Cardioverter-Defibrillator in the Prevention of Sudden Cardiac Death: A Narrative Review. Cureus. 2022;14(10):e30170. Available from: https://doi.org/10.7759/cureus.30170 DOI: https://doi.org/10.7759/cureus.30170

Friedman P, Murgatroyd F, Boersma LVA, Manlucu J, O’Donnell D, Knight BP, et al. Efficacy and Safety of an Extravascular Implantable Cardioverter–Defibrillator. N Engl J Med. 2022;387(16):1292-1302. Available from: https://doi.org/10.1056/nejmoa2206485 DOI: https://doi.org/10.1056/NEJMoa2206485

Hedayati Goudarzi MT, Moradi M, Abrotan S, Saravi M, Shirafkan H, Irilouzadian R, et al. Complications of Implantable Cardioverter Defibrillator and Their Potential Risk Factors in Patients with Hypertrophic Cardiomyopathy. Cardiol Res Pract. 2023;2023:4552100. Available from: https://doi.org/10.1155/2023/4552100 DOI: https://doi.org/10.1155/2023/4552100

Healey JS, Krahn AD, Bashir J, Amit G, Philippon F, McIntyre WF, et al. Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations: A Randomized, Multicenter Trial. Ann Intern Med. 2022;175(12):1658-65. Available from: https://doi.org/10.7326/m22-1566 DOI: https://doi.org/10.7326/M22-1566